The market’s harsh reaction to the Q4 miss seems unreasonable
08/02/24 -"Even though Q4 profitability fell short of the street’s expectations, the 2023 results met the management’s CER guidance. The management’s 2024 outlook was healthy as well. Still, the share price ..."
Pages
66
Language
English
Published on
08/02/24
You may also be interested by these reports :
26/07/24
The Q2 results came in ahead of expectations, driven by a strong showing across most target areas. As we had indicated the possibility earlier, the ...
26/07/24
The Q2 results beat the market’s expectations, driven by the robust momentum for Dupixent, the healthy trajectory for new launches, and strong growth ...
26/07/24
The outlook has improved, though challenges remain. The company initially lost credibility after announcing a weak 2024 outlook back in the autumn of ...
25/07/24
The Q2 results came in ahead of expectations, with healthy growth witnessed across the targeted areas. Consequently, the management revised its ...